# US 10,370,726 B2 · Detecting colorectal neoplasia

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,370,726 B2
- Document ID: US10370726B2
- Status: Granted
- Kind: B2
- Application number: 15/487,124
- Filed: 2017-04-13
- Published: 2017-10-19
- Granted: 2019-08-06
- Earliest claimed: 2016-04-14
- Assignees: Mayo Foundation for Medical Education and Research
- Applicants: Mayo Foundation for Medical Education and Research
- Inventors: David A. Ahlquist; William R. Taylor; John B. Kisiel; Tracy C. Yab; Douglas W. Mahoney
- Web page: https://patentgrep.com/patent/US10370726B2

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- G16H 50/20: for computer-aided diagnosis, e.g. based on medical expert systems
- C12Q 2600/112: Disease subtyping, staging or classification
- C12Q 2600/154: Methylation markers
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q 2600/16: Primer sets for multiplex assays
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA

## Abstract

Provided herein is technology for colorectal neoplasia screening and particularly, but not exclusively, to methods, compositions, and related uses for detecting the presence of colorectal neoplasia in 1) individuals at, older or younger than 50 years of age, or 2) individuals having Lynch Syndrome.

## Claims

### Claim 1

A method comprising:
extracting genomic DNA from a biological sample of a human individual suspected of having or having colorectal neoplasia, wherein the biological sample is a stool sample, a plasma sample, or a blood sample,
treating the extracted genomic DNA with bisulfite,
amplifying the bisulfite-treated genomic DNA using primers specific for nine or fewer DNA markers at least including primers specific for USP44, primers specific for OPLAH, and primers specific for LRRC4,
measuring the methylation level of the CpG site for the nine or fewer DNA markers at least including USP44, OPLAH, and LRRC4 by methylation-specific PCR, quantitative methylation-specific PCR, methylation-sensitive DNA restriction enzyme analysis, or bisulfite genomic sequencing PCR.

### Claim 2 (depends on 1)

The method of claim 1, wherein the biological sample is a tissue sample, a plasma sample, or a blood sample.

### Claim 3 (depends on 1)

The method of claim 1, wherein amplifying the bisulfite-treated genomic DNA using primers specific for USP44 is a set of primers that specifically binds at least a portion of a genetic region comprising chromosome 12 coordinates 95942010-95942240.

### Claim 4 (depends on 1)

The method of claim 1,
wherein amplifying the bisulfite-treated genomic DNA using primers specific for OPLAH is a set of primers that specifically binds at least a portion of a genetic region comprising chromosome 8 coordinates 145106349-145106456.

### Claim 5 (depends on 1)

The method of claim 1,
wherein amplifying the bisulfite-treated genomic DNA using primers specific for LRRC4 is a set of primers that specifically binds at least a portion of a genetic region comprising chromosome 7 coordinates 127671993-127672310.